Patterns of Opioid and Non-Opioid Analgesic Consumption in Patients with Post-COVID-19 Conditions
-
Published:2023-10-18
Issue:20
Volume:12
Page:6586
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Carrasco-Garrido Pilar12ORCID, Palacios-Ceña Domingo3ORCID, Hernández-Barrera Valentín1, Jiménez-Trujillo Isabel1ORCID, Gallardo-Pino Carmen1, Fernández-de-las-Peñas Cesar3ORCID
Affiliation:
1. Department of Medical Specialties and Public Health, Health Sciences Faculty, Universidad Rey Juan Carlos, Avenida Atenas s/n, Alcorcon, 28922 Madrid, Spain 2. Preventive Medicine and Public Health Teaching and Research Unit, Health Sciences Faculty, Rey Juan Carlos University, Avda. Atenas s/n. Alcorcón, 28922 Madrid, Spain 3. Department of Physical Therapy, Occupational Therapy, Rehabilitation and Physical Medicine, Health Sciences Faculty, Universidad Rey Juan Carlos, Avenida Atenas s/n, Alcorcon, 28922 Madrid, Spain
Abstract
Pain is a major health issue for healthcare systems, and access to pain treatment is a fundamental human right. Pain is a common symptom experienced in the post-COVID phase by a significant percentage of patients. This study describes the prevalence and associated factors associated with the use of opioid and non-opioid analgesics in subjects with post-COVID-19 condition. Sociodemographic data, post-COVID symptoms, health profile, and opioid and non-opioid analgesic consumption were collected in 390 subjects with post-COVID-19 condition. We analyzed the independent effect of all variables on opioid/non-opioid analgesic consumption by using logistic multivariate regressions. The prevalence of opioid and non-opioid analgesic consumption was 24.1% and 82.3%, respectively. Tramadol (17.18%) and codeine (7.95%) were the most commonly used opioid analgesics, and Paracetamol (70%) and ibuprofen (45.4%) were the most commonly used non-opioid analgesics. Females were more likely to consume non-opioid analgesics (aOR2.20, 95%CI 1.15, 4.22) than males. Marital status of married/partner vs. single (aOR2.96; 95% CI 1.43, 6.12), monthly income < EUR 1000 VS. > EUR 2000 (aOR3.81; 95% CI 1.37, 10.61), number of post-COVID symptoms < 5 (aOR2.64, 95%CI 1.18, 5.87), and anxiolytics consumption (aOR 1.85, 95%CI 1.05, 3.25) were associated with a greater likelihood of opioid analgesic consumption. Age > 55 years (aOR3.30, 95%CI 1.34, 8.09) and anxiolytics consumption (aOR2.61, 95%CI 1.36, 4.98) were associated with a greater likelihood of non-opioid analgesic consumption. Opioid analgesic consumption was highly associated (aOR 3.41, 95%CI 1.27, 6.11) with non-opioid analgesic consumption. The prevalence of opioid analgesic and non-opioid analgesic consumption in individuals with post-COVID-19 condition was 24.1% and 82.3%. Females with post-COVID-19 condition showed higher non-opioid analgesic consumption than men. Predictors of opioid consumption were marital status, lower monthly income, number of post-COVID symptoms, and anxiolytic consumption. Older age and anxiolytic consumption were predictors of non-opioid consumption.
Reference54 articles.
1. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis;Sun;J. Med. Virol.,2020 2. Ciaffi, J., Meliconi, R., Ruscitti, P., Berardicurti, O., Giacomelli, R., and Ursini, F. (2020). Rheumatic manifestations of COVID-19: A systematic review and meta-analysis. BMC Rheumatol., 4. 3. Kundakci B Neurological and musculoskeletal features of COVID-19: A systematic review and meta-analysis;Abdullahi;Front. Neurol.,2020 4. Headache as a symptom of COVID-19: Narrative review of 1-year research;Caronna;Curr. Pain. Headache Rep.,2021 5. Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology and management;Headache,2022
|
|